Last edition
News about "ocular neovascular diseases"
Remegen Partners with Santen To Commercialise RC28-E in Greater China and Asian Countries
RemeGen, a leading Chinese biopharmaceutical company, has entered into an exclusive licensing agreement for the ophthalmic innovative drug RC28-E with Santen China, a wholly-owned subsidiary of Santen Pharmaceutical.
Ocular Neovascular Diseases | 19/08/2025 | By Dineshwori | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members